3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Fallopian Tube Neoplasms
10
Ovarian Neoplasms
7
Endometrial Neoplasms
5
Breast Neoplasms
4
Prostatic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Osteosarcoma
2
Neuroendocrine Tumors
2
Neuroblastoma
2
Neoplasms
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Glioma
2
Ependymoma
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Recurrence
1
Interventions
lutetium Lu 177 dotatate
2
Magnetic Resonance Spectroscopy
2
olaparib
1
gallium Ga 68 dotatate
1
capivasertib
1
abemaciclib
1
Surveys and Questionnaires
1
Sunitinib
1
Specimen Handling
1
Lysine
1
Hydroxyurea
1
HhAntag691
1
Ga(III)-DOTATOC
1
GSK2256098
1
Everolimus
1
Bevacizumab
1
Arginine
1
Aminolevulinic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Meningioma
×
olaparib
×
30 days
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled